On September 12, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended updated 2023-2024 (monovalent, XBB-containing) mRNA Moderna and Pfizer-BioNTech COVID-19 vaccines.for high risk individuals.
The following clinical considerations were shared during the ACIP meeting:
The updated 2023-2024 COVID-19 vaccine is recommended at least two months after receiving the last COVID-19 vaccine dose.
People who are moderately or severely immunocompromised should complete a three-dose initial series with at least one dose of the 2023-2024 COVID-19 vaccine and may receive one or more additional 2023-24 COVID-19 vaccine doses.
Note: These recommendations are those of the CDC for high risk individuals. Further recommendations are made for young children (six months to five years). While other _often international_ medical sources of information have provided questions as to the appropriateness of certain vaccines for the general public, there is frequent agreement on the need for all those whose immunological systems are in some way challenged, as infection in these individuals can easily result in serious illness, even death.
Respectfully, Clifford Brown, OD, MPH, FAAO(D) CAPT/USPHS (Ret) Director of Public Health Custer County
Comments